Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 2

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 3

Conditions

Papillomavirus Infections 4Uterine Cervical Neoplasms 3Hepatitis B 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 36Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 29Papillomavirus Vaccines 22Vaccines 11Human Papillomavirus Recombinant Vaccine nonavalent 11Radiotherapy, Intensity-Modulated 7Human Papillomavirus DNA Tests 7Colposcopy 7Cisplatin 7Educational Status 6Carboplatin 6Blood Specimen Collection 6Vaccines, Synthetic 5Specimen Handling 5Early Intervention, Educational 5Vaginal Smears 4Methods 4Engerix-B 4fludarabine 3epigallocatechin gallate 3artesunic acid 3artemisinin 3Watchful Waiting 3Surveys and Questionnaires 3Patient Navigation 3Paclitaxel 3Imiquimod 3Hepatitis A Vaccines 3Cyclophosphamide 3halofantrine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Papillomavirus Infections × Engerix-B × Clear all
NCT00637195 2020-01-03

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

GlaxoSmithKline

Phase 3 Completed
152 enrolled 21 charts
Gynecologic

Uterine Cervical Neoplasms, Hepatitis B, Papillomavirus Infections

NCT00534638 2019-11-15

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

GlaxoSmithKline

Phase 4 Completed
34,412 enrolled 21 charts
Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00652938 2018-08-17

Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects

GlaxoSmithKline

Phase 3 Completed
744 enrolled 27 charts
Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01082861 2010-03-19

TANGO

National Institute for Public Health and the Environment (RIVM)

Phase 4 Terminated

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡